Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system.
Sci Rep
January 2025
Department of Pharmacology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Drug-induced eosinophilic pneumonia (EP) is an uncommon adverse drug reaction. Many drugs have been reported to cause EP, the evidence mainly being in the form of case reports/case series. This study aims to conduct an exploratory analysis of the United States Food and Drug Administration adverse event reporting system (FAERS) database to identify previously unknown drugs that can cause EP and supplement the available evidence for known culprit drugs.
View Article and Find Full Text PDFBackground: Cognitive impairment is a major symptom among patients with post-acute sequelae of COVID-19; the underlying pathogenesis is unknown. This impairment may be associated with changes in the level of plasma biomarkers of neurodegeneration and neuroinflammation.
Method: Plasma samples were collected from COVID-19 patients (Covpos, median 724 days from index SARS-CoV-2 infection), and from non-COVID-19 controls (Covneg; no history of SARS-CoV-2 infection and negative SARS-CoV-2 nucleocapsid antibody).
Biomarkers.
Alzheimers Dement
December 2024
Alzheimer's Disease Research Center, New York University Langone Health, New York, NY, USA.
Background: Cognitive impairment is one of the most frequently reported post-acute sequelae of COVID-19, yet the pathophysiology underpinning this symptom remains unknown. We aimed to explore the correlation of blood markers of inflammation, BBB disruption and neurodegeneration with MRI volume measurements in COVID-19 patients with and without cognitive impairment, and among patients with no prior history of COVID-19.
Method: We conducted a prospective study of COVID-19 patients (COV+; laboratory verified SARS-CoV-2 infection) and non-COVID-19 controls (COV-; no history of SARS-CoV-2 infection and negative SARS-CoV-2 nucleocapsid antibody).
Alzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
Alzheimer's Disease Research Center, New York University Langone Health, New York, NY, USA.
Background: Cognitive impairment is one of the most frequently reported post-acute sequelae of COVID-19, yet the pathophysiology underpinning this symptom remains unknown. We aimed to explore the correlation of blood markers of inflammation, BBB disruption and neurodegeneration with MRI volume measurements in COVID-19 patients with and without cognitive impairment, and among patients with no prior history of COVID-19.
Method: We conducted a prospective study of COVID-19 patients (COV+; laboratory verified SARS-CoV-2 infection) and non-COVID-19 controls (COV-; no history of SARS-CoV-2 infection and negative SARS-CoV-2 nucleocapsid antibody).
The Impact of High-Flow Nasal Oxygen Therapy on Swallowing Function and Aspiration in Patients and Healthy Adults: A Scoping Review.
Cureus
December 2024
College of Nursing, Kanto Gakuin University, Yokohama, JPN.
High-flow nasal oxygen therapy (HFNO) is highly versatile and employed in varied situations, including after extubation, in cases of respiratory failure, and at the end of life. However, its impact on swallowing function is not yet elucidated. Therefore, this scoping review aimed to clarify how HFNO affects swallowing function and whether it poses a risk for aspiration pneumonia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!